Top 200 #8
Quiz yourself by thinking what should be in
each of the black spaces below before clicking
on it to display the answer.
Help!
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antianxiety; Benzodiazepine (Short or Intermediate Acting) | Xanax | Alprazolam | Anxiety; panic disorder | Oral Tablet: 0.25, 0.5, 1, 2mg; ODT: 0.25, 0.5, 1, 2; ER Tablet: 0.5, 1, 2, 3mg; Oral Soln: 1mg/ml | Oral | Anxiety:0.25-0.5 tid Panic disorder: 0.5 tid max: 10mg/day | N/A | Possibly binds to various stereo-specific receptors in the CNS
🗑
|
||||||||||||||||||
| Benzodiazepine (Short-Intermediate Acting); Hypnotic | Restoril | Temazepam | Insomnia | Oral Capsule: 7.5, 15, 22.5, 30mg | Oral | 7.5-30mg at bedtime | N/A | Hypnotic agent belonging to the benzodiazepine class
🗑
|
||||||||||||||||||
| Antidiabetic; Ultra Rapid Acting Insulin | NovoLog; NovoLog Flexpen | Insulin Aspart (70/30) | Type 1&2 DM | SubQ Susp/Soln: 100U/ml (10ml vials) (3ml flexpen) | SubQ | Inject dose 5-10 minutes before a meal; dose varies | 2YO+ Inject dose 5-10 minutes before a meal; dose varies | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose
🗑
|
||||||||||||||||||
| Antidiabetic; Ultra Rapid Acting Insulin | Humalog; Humalog Kwikpen | Insulin Lispro | Type 1&2 DM | SubQ Susp/Soln: 100U/ml (10ml vials) (3ml kwik-pen) | SubQ | Inject dose 5-10 minutes before a meal; dose varies | 3YO+ Inject dose 5-10 minutes before a meal; dose varies | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose
🗑
|
||||||||||||||||||
| Antidiabetic; (R) Rapid Acting and (N) Intermediate Acting | Humulin N; Humulin R | Insulin | Type 1&2 DM | (N)Susp:100U/ml (R) soln: 100U/mL, 500U/mL | SubQ | dosages need to be individualized Type 1: 0.5-0.6 U/kg/day up to 3x /day Type2: 0.2-0.6 U/kg/day | 12 yo and older :same as adults | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose
🗑
|
||||||||||||||||||
| Antidiabetic; Long Acting Insulin | Lantus; Lantus Solostar | Insulin Glargine | Type 1&2 DM | SubQ Soln: 100U/ml Pen-Injector | SubQ | Individualized dosing for once daily (same time each day) | 6YO+ individualized dosing | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose
🗑
|
||||||||||||||||||
| Antidiabetic; Long Acting Insulin | levemir | Insulin Detemir | Type 1&2 DM | SubQ Soln: 100U/ml Pen-Injector | SubQ | Individualized dosing QD-BID | 2YO+ individualized dosing | Binds to insulin receptors on muscle and fat cells allowing for increased cellular uptake of glucose and subsequent decreases in blood glucose
🗑
|
||||||||||||||||||
| Antidiabetic; Dipeptidyl Peptidase IV Inhibitor | Januvia; Janumet | Sitagliptin Sitagliptin/ Metformin | Type 2 DM | Oral Tablet: Januvia:25, 50, 100mg Janumet:50/500,50mg/1000mg Janumet XR: 50/500,50/1000,100mg/1000mg | Oral | 100mg QD with or without food | N/A | DPP-4 inhibitor
=increase insulin and decrease glucagon
🗑
|
||||||||||||||||||
| Antidiabetic; GLP-1 Receptor Agonist | Victoza | Liraglutide | Type 2 DM | SubQ Soln: 6mg/ml Pen-Injector | SubQ | 0.6-1.2mg QD, may increase to 1.8mg QD | N/A | GLP-1 receptor agonist that acts to increase insulin release in the presence of elevated glucose concentrations, decrease glucagon secretion in a glucose-dependent manner, and delay gastric emptying
🗑
|
||||||||||||||||||
| Antidiabetic; GLP-1 Receptor Agonist | Byetta, Bydureon | Exenatide | Type 2 DM | SubQ Soln: (pen-injector) 5mcg/0.2ml 10mcg/0.4ml | SubQ | IR: initial = 5mcg BID within 60mins before AM & PM meal (approx. 6 hrs apart); Maintenance: may increase to 10mcg BID | N/A | Acts as an incretin mimetic agent to enhance glucose-dependent insulin secretion
🗑
|
||||||||||||||||||
| Antidiabetic; Thiazo-lidinedione | Actos | Pioglitazone | Type 2 DM | Oral Tablet: 15, 30, 45mg | Oral | Initial = 15-30mg QD; max of 45mg QD | N/A | Thiazolidinedione antidiabetic agent & PPARĪ³ agonist, is dependent on the presence of insulin for its MOA
🗑
|
||||||||||||||||||
| Biguanide; Hypoglycemic | Glucophage; Riomet; Fortamet; | Metformin; | Type 2 DM | Oral Tablet: 500, 850, 1000mg; ER Tablet: 500, 750, 1000mg; Oral Soln(Riomet): 500mg/5ml | Oral | Type 2: IR: 500 BID-850 QD.Max: 2550mg/day ER: 1000 QD.max: 2000mg/day | >10 yo: IR: same as adults ER: n/a | Lowers both basal and postprandial glucose levels in type 2 DM pts through several mechanisms: decreases hepatic glucose production, decrease intestinal absorption, and increases peripheral glucose uptake & utilization by improving insulin sensitivity
🗑
|
||||||||||||||||||
| Biguanide; Hypoglycemic; 2nd gen. sulfonylurea | Glucovance | Metformin/Glyburide | Type 2 DM | Oral Tablet: Gly/Met 1.25mg/250mg 2.5mg/500mg 5.0mg/500mg | Oral | 1.25/250 bid Max: 10mg/2000mg | N/A | Metformin MOA + Glyburide stimulates pancreatic beta cells to produce insulin.
🗑
|
||||||||||||||||||
| Amphetamine, CNS Agent/ Stimulant | Adderall; Adderall XR | Amphetamine Salts | ADHD; narcolepsy | ER Capsule: 5, 10, 15, 20, 25, 30mg; IR Tablet: 5, 7.5, 10, 12.5, 15, 20, 30mg | Oral | ADHD: 20mg ER cap QD; 5mg IR tab QD-BID Narcolepsy: 5-60mg IR tab QD or divided doses | 3YO+ dose varies based on age | Noncatechol sympathetic amine with CNS stimulant activity; purported to block the reuptake of NE and dopamine into the presynaptic neuron & increase their release into the extraneuronal space
🗑
|
||||||||||||||||||
| Amphetamine Related; CNS Agent/ Stimulant | Concerta; Daytrana; Ritalin; Metadate; Methylin | Methylphenidate | ADHD; narcolepsy | Metadate:ER-C: 10,20,30,40,50,60mg; ER-T:20mg. Ritalin:T: 5,10,20mg; ER-T:10,20,30,40 Concerta:ER Tab: 10,18,20,27,36,54mg Methylin:Chew T: 2.5,5,10mg;Soln:5mg, 10mg/5mL Patch(Daytrana): 10, 15 20,30mg/9hr | Oral, Topical | Varies usually QAM Max: 60mg/day | 6YO+ Dose varies (Patch may be used on ped.) | Blocks the reuptake of NE and dopamine into the presynaptic neuron, thus increasing the concentrations of these monoamines in the extraneuronal space
🗑
|
||||||||||||||||||
| Amphetamine Related; CNS Stimulant | Focalin XR | Dexmethylphenidate | ADHD | ER Capsule(XR): 5, 10, 15, 20, 25, 30, 35, 40mg; IR Tablet(Focalin): 2.5, 5, 10 | Oral | Initial = 10mg QAM, adjust dose weekly in 10mg increments (max of 40mg/day) | 6YO+ ER, initial: 5mg QAM, adjust weekly in 5mg inc. Max ER: 30mg/day Max IR: 20mg/day | Thought to block the reuptake of NE and DA into the presynaptic neuron, increasing the concentrations of these monoamines in the extraneuronal space
🗑
|
||||||||||||||||||
| Amphetamine; CNS Stimulant | Vyvanse | Lisdexamfetamine Dimesylate | ADHD, Binge eating disorder | Oral Capsule: 10, 20, 30, 40, 50, 60, 70mg | Oral | Initial: 30mg QAM, may increase by increments of 10 or 20mg per day at approx. 1 week intervals Max: 70mg/day | 6YO+ same dosing as adults | May block the reuptake of NE and DA
🗑
|
||||||||||||||||||
| Antianxiety; Anticonvulsant; Benzodiazepine (Short or Intermediate Acting) | Klonopin | Clonazepam | Panic disorder; Seizure | Oral Tablet: 0.5, 1, 2mg; ODT: 0.125, 0.25, 0.5, 1, 2mg | Oral | 0.5 bid-tid.Max: 4mg/day | seizure: >10yo: 0.5 tid <10yo: 0.01-0.03 bid-tid | Believed to enhance GABA activity
🗑
|
||||||||||||||||||
| Antianxiety; Anticonvulsant; Benzodiazepine (Long Acting) | Valium | Diazepam | Alcohol withdrawal syndrome; anxiety; sedation; seizure; skeletal muscle spasm; status epilepticus | Inj. Soln: 5mg/ml; Oral concentrate: 5mg/ml; Oral Tablet: 2, 5, 10mg; Rectal Gel: Diastat AcuDial: :10, 20mg. Diastat Pediatric: 2.5mg IM device: 10mg/2mL | Oral, injection, IM, Rectal | 2-10mg bid-qid | > 6mo: 1-2.5 mg tid-qid | Reduces neuronal depolarization resulting in decreased action potentials. Enhances action of GABA by tightly binding to GABA-A receptors
🗑
|
||||||||||||||||||
| Antianxiety; Benzodiazepine (Short or Intermediate Acting) | Ativan | Lorazepam | Anxiety; insomnia; premedication for anesthetic procedure; status epilepticus | Inj. Soln: 2mg/ml, 4mg/ml; Oral concentrate: 2mg/ml; Oral Tablet: 0.5, 1, 2mg | Oral, Injection | anxiety: 1-2 mg bid-tid insomnia: 2-4 mg QHS | 12YO+ dose varies | Binds highly to the GABA-BZ receptor complex without displacing GABA
🗑
|
Review the information in the table. When you are ready to quiz yourself you can hide individual columns or the entire table. Then you can click on the empty cells to reveal the answer. Try to recall what will be displayed before clicking the empty cell.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Created by:
scottamus123
Popular Pharmacology sets